In a pooled analysis from four clinical trials, enrolling patients with tissue confirmed BRAF V600E/K mutant melanoma; copies of mutant BRAF were identified in 76% (V600E) and 81% (V600K) of 732 baseline plasma samples using BEAMing (beads, emulsion, amplification). The gene discussed is BRAF; the disease is melanoma.